AstraZeneca stock drops
AstraZeneca stock drops after lung cancer drug trial setback
London-listed AstraZeneca shares fell more than 5% on Tuesday after results from the company's lung cancer trials showed that its experimental precision drug did not significantly improve overall survival results for patients.
AstraZeneca shares hit by lung cancer drug trial results
Shares in AstraZeneca dropped nearly 5 per cent on Tuesday after its failure to hit a target in trials for a next-generation lung cancer drug set back its ambitions to offer precision oncology treatments to more patients.
AstraZeneca Shares Slump After Cancer Drug Misses Key Target
AstraZeneca shares slumped after its key lung-cancer drug trial failed necessary targets that could risk U.S. Food & Drug Administration approval in the coming weeks. AstraZeneca shares slid 5% to 121.
AstraZeneca shares drop as lung cancer drug trial fails to improve survival
London-listed shares of AstraZeneca fell on Tuesday after results from the company's lung cancer trials showed that its experimental precision drug did not significantly improve overall survival results for patients.
AstraZeneca Faces Setback From Lung Cancer Drug's Disappointing Trial Results
KEY TAKEAWAYS A Phase 3 trial found AstraZeneca's experimental lung cancer drug datopotamab deruxtecan did not significantly improve patients' overall survival rates.The results from the trial showed that the overall survival rate "did not reach statistical significance,
AstraZeneca Sees Positive Survival Data in Recent Lung-Cancer-Treatment Trials
AstraZeneca said Monday that recent phase-three trials for its lung-cancer-treatment datopotamab deruxtecan showed a clinically meaningful trend toward improving overall survival. The pharmaceutical company said the treatment showed median overall survival of nearly 15 months in patients with advanced nonsquamous non-small cell lung cancer that were observed in the Tropion-Lung01 Phase III trial.
AstraZeneca says lung cancer drug trial shows no significant improvement in overall survival
Detailed results from one of AstraZeneca's key lung cancer trials released on Monday showed that its experimental precision drug did not significantly improve overall survival results for patients in the trial.
AstraZeneca shares fall 5% on disappointing lung cancer drug trial results
AstraZeneca shares fell more than 5% Tuesday morning, the biggest one-day drop in seven months, after the British pharmaceutical giant announced disappointing lung cancer drug trial results.
AstraZeneca falls Wednesday, underperforms market
Shares of AstraZeneca PLC AZN inched down 0.79% to £123.08 Wednesday, on what proved to be an all-around rough trading ...
Kepler Capital Sticks to Their Hold Rating for AstraZeneca (AZN)
In a report released on September 10, David Evans from Kepler Capital maintained a Hold rating on AstraZeneca (AZN – Research Report), ...
Ex-AstraZeneca Sales Worker Beats Bid to Toss Vaccine Bias Case
A former AstraZeneca Pharmaceuticals LP sales worker adequately alleged she was fired after the company rejected her request ...
Zawya2h
AstraZeneca earns 3 different workplace certifications across its operations in North Africa and Levant
AstraZeneca certified as a Best Place to Work for all in Jordan, Lebanon, Iraq, Tunisia, Algeria and Morocco based on ...
FiercePharma2d
AstraZeneca's Alexion loses $130M to Syntimmune shareholders in post-merger payment suit
When AstraZeneca’s Alexion picked up rare disease specialist Syntimmune in 2018 for $ | A Delaware judge agreed that ...
AstraZeneca’s Promising NSCLC Treatment: A Buy Rating Amidst Breakthrough Developments
AstraZeneca (AZN – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Eric Le ...
Bloomberg Talks: Astrazeneca CEO Claude Roland Soriot
Curating today’s top interviews from around Bloomberg News. Hear conversations with the biggest names in finance, politics ...
AstraZeneca PLC ADR falls Wednesday, underperforms market
AstraZeneca PLC ADR closed $7.15 short of its 52-week high ($87.68), which the company reached on August 30th.
FTSE 100 falls as AstraZeneca weighs; slowing wage growth cements rate cut bets
London's FTSE 100 inched lower on Tuesday amid broad declines, with AstraZeneca weighing on the benchmark index while cooling ...